패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

MediciNova, Inc. 10 애널리스트 중 2 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
David Buck	B. Riley Securities, Inc.
Yen Ting Chen	Credit Suisse
Jason Kolbert	D. Boral Capital LLC.

MediciNova 배당금 및 환매

배당금 기준 확인 0/6

주요 정보

최근 배당금 및 환매 업데이트

Recent updates

Medicinova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MediciNova, Inc. to Report Q3, 2024 Results on Nov 14, 2024

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

MediciNova, Inc. Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

MediciNova, Inc. to Report Q2, 2024 Results on Aug 09, 2024

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

MediciNova, Inc. Announces Data from Phase 1B/2A Clinical Trial of Mn-166 (Ibudilast) in Glioblastoma Patients At the American Society of Clinical Oncology (Asco) Annual Meeting 2024

MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

MediciNova, Inc., Annual General Meeting, Jun 11, 2024

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova, Inc. to Report Q1, 2024 Results on May 10, 2024

MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Medicinova Announces New Data and Results of Mn-166 (Ibudilast) in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology

Price target increased by 69% to US$27.00

MediciNova, Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

MediciNova, Inc. Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

MediciNova, Inc. Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

MediciNova, Inc. to Report Q3, 2023 Results on Nov 10, 2023

Price target decreased by 41% to US$16.00

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

MediciNova, Inc. Receives A Notice of Intention to Grant for A New Patent Covering MN-166 (Ibudilast) for the Treatment of Macular Injury in Europe

Less than half of directors are independent

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova, Inc. Announces Presentation of Results from the Phase 2B Trial of Mn-166 (Ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

MediciNova Announces Health Canada Grants Authorization to Commence Multi-Arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID

MediciNova, Inc. Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder

MediciNova, Inc. Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma

MediciNova Receives Notice of Allowance for A New Patent Covering Mn-001 and Mn-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada

MediciNova, Inc. Receives Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil

MediciNova, Inc. Completes Phase I Clinical Trial to Evaluate MN-166 10 MG Intravenous Infusion in Healthy Volunteers

MediciNova, Inc. Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presents at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

Price target decreased to US$13.00

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

MediciNova, Inc. to Report Q3, 2022 Results on Nov 11, 2022

MediciNova to get US patent for MN-166 to treat brain cancer

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada

MediciNova's MN-166 to be part of study to treat Long COVID

First half 2022 earnings released

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea

MediciNova, Inc Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

MediciNova, Inc. to Report Q2, 2022 Results on Aug 12, 2022

MediciNova, Inc. Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)

MediciNova begins study of parenteral formulation of MN-166

MediciNova announces extension of BARDA contract for Ibudilast development

MediciNova, Inc. Announces Executive Changes

MediciNova, Inc. Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

Price target decreased to US$13.00

MediciNova, Inc. to Report Q1, 2022 Results on May 13, 2022

MediciNova, Inc. Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

MediciNova, Inc. Announces Plans for A Phase 2 Trial of Mn-001 (Tipelukast) in Nafld with Type 2 Diabetes Mellitus and Hypertriglyceridemia

MediciNova, Inc. Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova, Inc. announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada

MediciNova Receives Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe

MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS

MediciNova, Inc. Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND

Medicinova, Inc. Announces New Data Regarding Mn-166 (ibudilast) in Glioblastoma Presented At the 26Th Annual Meeting of the Society for Neuro-Oncology

MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

MediciNova, Inc. Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND

MediciNova: The Pain Of A Positive Outlook

Price target decreased to US$16.00

Chief Medical Officer & Director exercised options to buy US$229k worth of stock.

Consensus revenue estimates increase to US$15.5m

Chief Financial Officer Edward Stepanow has left the company

MediciNova, Inc.(NasdaqGM:MNOV) dropped from Russell 3000 Growth Index

MediciNova, Inc. Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal

MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study

MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury